
News|Articles|February 6, 2006
New product newswire: February 2, 2006
The FDA gave marketing approval to ZLB Behring, King of Prussia,Pa., for an immunoglobulin (Ig) replacement therapy that can beself-administered by patients at home. Vivaglobin (immune globulinsubcutaneous [human]), indicated for treating patients with primaryimmunodeficiency, delivers antibodies subcutaneously, as analternative to intravenous infusions of immunoglobulin, to fightlife-threatening infections. The firm can be reached at (610)878-4000.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Medication Management Lags Due to Fragmented Data Systems
2
Patient Worry, Identity Shape Adults’ Vaccine Perception
3
Equity-Based Strategies Best for Improving Pneumococcal Vaccine Rates
4
Pharmacy Law Lowdown: CVS Caremark’s Settlement with FTC
5
























